[go: up one dir, main page]

WO2024036197A3 - Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome - Google Patents

Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome Download PDF

Info

Publication number
WO2024036197A3
WO2024036197A3 PCT/US2023/071908 US2023071908W WO2024036197A3 WO 2024036197 A3 WO2024036197 A3 WO 2024036197A3 US 2023071908 W US2023071908 W US 2023071908W WO 2024036197 A3 WO2024036197 A3 WO 2024036197A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
methods
conditions associated
treating diseases
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/071908
Other languages
French (fr)
Other versions
WO2024036197A2 (en
Inventor
Roger A. Johns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to AU2023324170A priority Critical patent/AU2023324170A1/en
Publication of WO2024036197A2 publication Critical patent/WO2024036197A2/en
Publication of WO2024036197A3 publication Critical patent/WO2024036197A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating diseases and conditions associated with the priming and activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome. In particular embodiments, the method comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
PCT/US2023/071908 2022-08-09 2023-08-09 Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome Ceased WO2024036197A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023324170A AU2023324170A1 (en) 2022-08-09 2023-08-09 Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263370851P 2022-08-09 2022-08-09
US63/370,851 2022-08-09

Publications (2)

Publication Number Publication Date
WO2024036197A2 WO2024036197A2 (en) 2024-02-15
WO2024036197A3 true WO2024036197A3 (en) 2024-05-02

Family

ID=89852492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071908 Ceased WO2024036197A2 (en) 2022-08-09 2023-08-09 Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome

Country Status (2)

Country Link
AU (1) AU2023324170A1 (en)
WO (1) WO2024036197A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170276688A1 (en) * 2006-12-18 2017-09-28 The Johns Hopkins University Anti-himf antibodies to treat lung diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170276688A1 (en) * 2006-12-18 2017-09-28 The Johns Hopkins University Anti-himf antibodies to treat lung diseases

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN 10 February 2021 (2021-02-10), ANONYMOUS: "immunoglobulin variable region, partial [Homo sapiens]", XP093168416, Database accession no. QRG33514.1 *
DATABASE PROTEIN 10 September 2012 (2012-09-10), ANONYMOUS: "anti-oligomeric synuclein single-chain Fv antibody D5E [synthetic construct]", XP093168422, Database accession no. AFR23376.1 *
DATABASE PROTEIN 17 September 2019 (2019-09-17), ANONYMOUS: "IGL c3598_light_IGKV1D-39_IGKJ1, partial [Homo sapiens]", XP093168408, Database accession no. QEP13659.1 *
DATABASE PROTEIN 18 May 2021 (2021-05-18), ANONYMOUS: "anti-peanut 2S albumin immunoglobulin heavy chain variable region, partial [Homo sapiens]", XP093168411, Database accession no. QVG74477.1 *
DATABASE PROTEIN 21 December 2020 (2020-12-21), ANONYMOUS: "MAG: Ig-like domain-containing protein [Gemmatimonadetes bacterium]", XP093168421, Database accession no. MBI2407530.1 *
DATABASE PROTEIN 23 July 2016 (2016-07-23), ANONYMOUS: "immunoglobulin heavy chain variable region, partial [synthetic construct]", XP093168415, Database accession no. ABQ50854.1 *
DATABASE PROTEIN 25 July 2016 (2016-07-25), ANONYMOUS: "anti-canine dendritic cell scFv antibody, partial [synthetic construct]", XP093168403, Database accession no. ADP21080.1 *
DATABASE PROTEIN 25 July 2016 (2016-07-25), ANONYMOUS: "anti-TNF alpha single chain Fv antibody, partial [synthetic construct]", XP093168424, Database accession no. AEX15593.17 *
DATABASE PROTEIN 26 July 2016 (2016-07-26), ANONYMOUS: "anti-fluorescein immunoglobulin light chain variable region, partial [Homo sapiens]", XP093168418, Database accession no. CAQ55833.1 *
DATABASE PROTEIN 26 July 2016 (2016-07-26), ANONYMOUS: "immunoglobulin light chain variable region, partial [Homo sapiens]", XP093168405, Database accession no. AAK94805.1 *
DATABASE PROTEIN 28 July 2012 (2012-07-28), ANONYMOUS: "scFV antibody, partial [synthetic construct]", XP093168428, Database accession no. AFN94004.1 *

Also Published As

Publication number Publication date
WO2024036197A2 (en) 2024-02-15
AU2023324170A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
EP3411400B1 (en) Treatment of inflammatory diseases with inhibitors of c5a activity
CN104144948B (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig backbone for therapy
WO2020259605A1 (en) Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof
FR3025518B1 (en) LIGANDS POTENTIATING THE BIOACTIVITY OF GONADOTROPHINS
KR20240170594A (en) Treating hidradenitis suppurativa with il-17 antagonists
MX2022001403A (en) Methods of administering anti-siglec-8 antibodies and corticosteroids.
MX2023010661A (en) Lilrb1 and lilrb2-binding molecules and uses therefor.
DK2822966T3 (en) Treatment of mucositis with immunoglobulin a
WO2024036197A3 (en) Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome
US12162951B2 (en) Anti-idiotypic antibodies against anti-KLK2 antibodies
JP2022501356A (en) Use of cathepsin S inhibitors for the formation of anti-drug antibodies
JP2025032243A (en) Bispecific antibodies for use in the treatment of hidradenitis suppurativa - Patent Application 20070233334
KR20240021800A (en) antibody composition
WO2024173838A3 (en) Anti-tl1a antibody compositions and methods of treatment in the bile duct
WO2024173865A3 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
WO2022091010A1 (en) Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition
Prayitno The role of COX-2, caspase-1 and IL-17 in pericoronitis-related inflammation due to lower third molar impaction
US20250270309A1 (en) Antibodies and methods targeting interleukin-19
US20250320288A1 (en) Method of treating vitiligo with interferon-gamma antibody
KR102102321B1 (en) Method for screening of sunlight protection functional material and method for evaluating sunlight protection effect
US20210261656A1 (en) Compositions and methods for treating autoimmune inner ear disease
WO2024133132A9 (en) Anti-tgfbeta receptor 1 antibodies and uses thereof
CN117257939A (en) Liquid preparation containing PEG modified antibody as active ingredient
EP4240761A1 (en) Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
WO2020259593A1 (en) Preparations containing anti-lag-3 antibody, and preparation method therefor and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853504

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2023324170

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023324170

Country of ref document: AU

Date of ref document: 20230809

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23853504

Country of ref document: EP

Kind code of ref document: A2